Abstract

The present study was undertaken to characterize and identify the insulin-like growth factor binding proteins (IGF BPs) secreted by placental cells and their possible modulatory effect on IGF-I binding to cell surface receptors. The experimental approach taken was comparative characterization of binding and internalization of IGF-I and its analog, [Gln(3), Ala(4), Tyr(15), Leu(16) (QAYL)]IGF-I, with reduced affinity for IGF BP, in two different placental cell culture models. One was human placental trophoblast in primary culture and the other, JEG-3 cells, a human choriocarcinoma cell line, representing placental trophoblasts. Binding of [(125)I]IGF-I in both trophoblast and JEG-3 cells was time and temperature dependent. At 37°C, the plateau of [(125)I]IGF-I binding to both the cells (1-2% specific binding per 10(5) cells) was reached by 40-60 min. At 4°C, the time required to reach the plateau in both cells was increased to ∼4h. The maximum binding of [(125)I]IGF-I to trophoblasts, however, was ∼2 times higher than at 37°C, whereas in JEG-3 cells binding remained the same. Internalization of [(125)I]IGF-I in trophoblast cells was low and temperature independent. At both 37 and 4°C, ≤30% of the total cell-associated [(125)I]IGF-I was internalized. In contrast, internalization of [(125)I]IGF-I in JEG-3 cells was rapid and temperature dependent. At 37°C, ≥60% of the total cell-associated [(125)]IGF-I was internalized by 40-60min. At 4°C, internalization was slow and did not exceed 10% of the total cell-associated radioactivity. Binding of [(125)I-QAYL]IGF-I to trophoblasts, in comparison to [(125)I]IGF-I, was significantly different. The binding was undetectable at 37°C and it was low at 4°C. In JEG-3 cells, however, the binding and internalization of [(125)I]-QAYL]IGF-I at both the temperatures were comparable to that of [(125)I]IGF-I. Further characterization of the two [(125)I]IGF-I bindings to the different placental cells was achieved by binding competition studies using unlabelled IGF-I, [QAYL]IGF-I and [Leu]IGF-I, another analog of IGF-I, [Leu(24), 1-62]IGF-I with reduced affinity for the IGF-I receptor, and α-IR3, a monoclonal antibody to the IGF-I receptor. The different potencies of IGF-I and its analogs, and α-IR3 in competing binding of two [(125)I]IGF-Is in the different cells suggested that binding of IGF-I to JEG-3 cells was predominantly to IGF-I receptor, whereas to trophoblast cells it was to IGF BP. This was confirmed by affinity cross-linking studies. The major affinity cross-linked [(125)I]IGF-I complex in trophoblast cells was shown to be a protein of Mr. ∼43 kDa, corresponding to IGF BP-3. In JEG-3 cells, the major cross-linked [(125)I]IGF-I and-[QAYL]IGF-I complexes were proteins of Mr ∼130 kDa and >260 kDa, corresponding to the monomeric and multimeric forms of IGF-I receptor. The ∼43 kDa complex in trophoblast was confirmed to be IGF BP-3 by identification of the characteristics of the IGF BP secreted by trophoblast by Western ligand and immunoblots of the conditioned media. JEG-3 cells did not secrete IGF BP. In conclusion, the membrane associated IGF BP-3 in trophoblast cells, shown here, imply anin vivo modulatory effect of membrane bound IGF BP-3 on IGF-I action in placenta. JEG-3 cells, not secreting IGF-BP, offer an attractive model to study the interactive mechanism of IGF-I and IGF BP-3 actions on the placenta.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.